Michael J. Bourque
Known title: EVP, CFO & TreasurerCIK: 0001638420
Michael J. Bourque's purchase track record
Michael J. Bourque has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/3/2025 | INGN | $25K | -21.8% | -0.4% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INGN | ▲ Buy | Grant | 874 | $5K | 3/1/2026 | View on chart |
| INGN | ▲ Buy | Option Exercise | 25,000 | $0 | 3/1/2026 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 9,338 | $57K | 3/1/2026 | View on chart |
| INGN | ▲ Buy | Grant | 28,875 | $0 | 3/1/2026 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 10,615 | $65K | 3/1/2026 | View on chart |
| INGN | ▲ Buy | Option Exercise | 17,007 | $0 | 3/1/2026 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 6,353 | $39K | 3/1/2026 | View on chart |
| INGN | ▲ Buy | Grant | 1,500 | $12K | 9/1/2025 | View on chart |
| INGN | ▲ Buy | Open Market | 3,000 | $25K | 3/3/2025 | View on chart |
| INGN | ▲ Buy | Grant | 600 | $5K | 3/1/2025 | View on chart |
| INGN | ▲ Buy | Option Exercise | 25,000 | $0 | 3/1/2025 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 9,838 | $82K | 3/1/2025 | View on chart |
| INGN | ▲ Buy | Grant | 47,625 | $0 | 3/1/2025 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 18,741 | $156K | 3/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Medical device growth debate touches Inogen sector
A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.
Medical device growth debate touches Inogen sector. A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.